Advanced Search
Contact | Corporate | Help

A Study of Apo2L/TRAIL Administered in Combination With Camptosar(R)/Erbitux(R) Chemotherapy or FOLFIRI (With or Without Bevacizumab) in Subjects With Previously Treated Metastatic Colorectal Cancer

Sponsors:
  • Genentech
Phases:
  • Phase I
IndicationsAcronym:
  • Colorectal Cancer
Age Groups:
  • Adult
  • Senior
Gender:
Both
Names:
  • Drug: APO2L/TRAIL
  • Drug: bevacizumab
  • Drug: cetuximab
  • Drug: FOLFIRI regimen
  • Drug: irinotecan
Enrollment:
52

Additional information about NCT00671372.


SourceSolution © 2008-2012